Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (202)

« Back to Publications

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB.

Freixeiro P. et al, (2026), NPJ Vaccines

Consultation report - gonococcal immunoassays and standards for vaccine development.

MacLennan CA. et al, (2026), Vaccine, 86

Navigating through uncertainty-Experience from the UK national VEXAS MDT.

Pietsch D. et al, (2026), Br J Haematol, 208, 1306 - 1313

The invasive non-typhoidal Salmonella vaccine landscape: Innovations and challenges ahead.

Revie NM. et al, (2026), Vaccine, 76

The age-specific concentrations and seroprevalence of antibodies against Salmonella Enteritidis (O:9) and Salmonella Typhimurium (O:4,5) across three sites in Kenya.

Muthumbi EM. et al, (2026), J Infect Dis

Vaccines and antimicrobial resistance: from science to policy-summary and outcomes.

MacLennan CA. et al, (2026), Philos Trans R Soc Lond B Biol Sci, 381

Lessons from COVID-19: the 100 Days Mission and antimicrobial resistance.

Hatchett R. and MacLennan CA., (2026), Philos Trans R Soc Lond B Biol Sci, 381

The immunology of infection

Gilchrist JJ. et al, (2026), Medicine United Kingdom, 54, 1 - 8

Vaccines and antimicrobial resistance: from science to policy-introduction

MacLennan CA. and Davies S., (2026), PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 381

Estimating the economic burden of invasive non-typhoidal Salmonella infections in low- and middle-income countries.

Lee J-S. et al, (2025), BMJ Glob Health, 10

Cross-comparison study of three ELISA methodologies to measure Shigella Sonnei O-antigen serum IgG.

Stickings P. et al, (2025), mSphere, 10

Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.

Excler J-L. et al, (2025), Vaccine, 62

Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study.

Al-Hakim A. et al, (2025), Lancet Rheumatol, 7, e472 - e484

BactiVac, the Bacterial Vaccines Network.

MacLennan CA. et al, (2025), Vaccine, 57

Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.

Ibarz-Pavon AB. et al, (2025), Vaccine, 56

Load More

1
2
3
4
5
6
7
...
»